Other subtypes of pediatric AML, characterized by a favorable prognosis, are those involving core binding factor (CBF), accounting for approximately 20–25% of pediatric AML cases [11], such as t(8;21) (q22;q22) and inv(16),which lead to the fusion genes RUNX1-RUNX1T1 and CBFB-MYH11, respectively. This evidence concerns the gene CBFB and acute myeloid leukemia.